Integrated BioPharma Reports September 30, 2026 Quarterly Results
Integrated BioPharma reported lower revenue and a shift to operating and net losses for the quarter ended September 30, 2026, compared with the same quarter in 2025.
Integrated BioPharma, Inc. (OTCQX:INBP) reported financial results for the quarter ended September 30, 2026, including lower revenue and losses at both the operating and net income levels compared with the quarter ended September 30, 2025.
Revenue for the quarter ended September 30, 2026 was $9.9 million, compared with $12.7 million for the quarter ended September 30, 2025. The company reported a decrease of $2.8 million or approximately 22.0%.
Riva Sheppard and Christina Kay, Integrated BioPharma’s Co-Chief Executive Officers, said revenue decreased by approximately 22% between the two quarters. They also reported that the company’s two largest customers in its Contract Manufacturing Segment accounted for approximately 88% of total revenue in the quarter ended September 30, 2026, compared with approximately 87% in the quarter ended September 30, 2025.
Integrated BioPharma recorded an operating loss of $1.0 million for the quarter ended September 30, 2026. In the corresponding quarter of 2025, the company reported operating income of $0.2 million.
The company’s net result was a net loss of approximately $0.7 million for the quarter ended September 30, 2026, compared with net income of approximately $0.1 million for the quarter ended September 30, 2025. Diluted net loss per share was $(0.02) for the 2026 quarter, compared with diluted net income per share of $0.00 for the 2025 quarter.
Integrated BioPharma is primarily engaged in manufacturing, distributing, marketing and selling vitamins, nutritional supplements and herbal products. The company is identified in the announcement as trading on OTCQX under the ticker symbol INBP.
Integrated BioPharma said its forward-looking statements involve risks, uncertainties and assumptions and are not guarantees of future performance. The company identified potential risks including changes in general economic and business conditions, competition and competing products, the timing of regulatory approvals and new product introductions, changes in industry capacity, pricing pressure, regulatory changes and obstacles, the availability of qualified personnel, and the loss of significant customers or suppliers.
Other risks identified by the company include inflation, including inflationary pressures from tariffs, tightened labor markets and its ability to expand its customer base. Integrated BioPharma said actual results could differ materially from those expressed or implied by forward-looking statements and that such statements should not be relied upon for investment purposes.
Integrated BioPharma, Inc. reported its financial results for the quarter ended September 30, 2026. The announcement compared the quarter with the quarter ended September 30, 2025.
The results cover the quarter ended September 30, 2026, with comparative figures for the quarter ended September 30, 2025. The company also provided a summary of its financial results for the three months ended September 30, 2026 and 2025.
Integrated BioPharma, Inc.’s revenue was $9.9 million for the quarter ended September 30, 2026, compared with $12.7 million for the quarter ended September 30, 2025. The company reported a decrease of $2.8 million or approximately 22.0%.
Integrated BioPharma, Inc. reported an operating loss of $1.0 million for the quarter ended September 30, 2026. This compared with operating income of $0.2 million for the quarter ended September 30, 2025.
Integrated BioPharma, Inc. reported a net loss of approximately $0.7 million for the quarter ended September 30, 2026, compared with net income of approximately $0.1 million for the quarter ended September 30, 2025. Diluted net loss per share was $(0.02) for 2026, compared with diluted net income per share of $0.00 for 2025.
Integrated BioPharma, Inc.’s Co-Chief Executive Officers, Riva Sheppard and Christina Kay, stated that revenue from the company’s two largest customers in its Contract Manufacturing Segment represented approximately 88% of total revenue in the quarter ended September 30, 2026. The comparable figure was approximately 87% for the quarter ended September 30, 2025.
Riva Sheppard and Christina Kay, the company’s Co-Chief Executive Officers, stated that revenue decreased by approximately 22% in the quarter ended September 30, 2026 from the quarter ended September 30, 2025. They also highlighted the proportion of total revenue generated by the two largest customers in the Contract Manufacturing Segment.
Integrated BioPharma, Inc. is engaged primarily in manufacturing, distributing, marketing and selling vitamins, nutritional supplements and herbal products.
Integrated BioPharma, Inc. is identified in the announcement as trading on OTCQX under the ticker symbol INBP.
Integrated BioPharma, Inc. identifies risks including changes in general economic and business conditions; loss of market share through competition; competing products; the timing of regulatory approval and new product introductions; changes in industry capacity; pricing pressure; regulatory changes and obstacles; availability of qualified personnel; loss of significant customers or suppliers; inflation, including inflationary pressures from tariffs; tightened labour markets; and the company’s ability to expand its customer base. The company also states that its forward-looking statements involve risks, uncertainties and assumptions, are not guarantees of future performance, should not be relied upon for investment purposes, and may differ materially from actual results.